Meet the lean, keen biotech episode artwork

EPISODE · Apr 28, 2023 · 59 MIN

Meet the lean, keen biotech

from Molecule to Market: Inside the outsourcing space · host Raman Sehgal

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with  Ian Walters, CEO and Chairman at Portage Biotech. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Ian, covering: What Ian learned from his time working with a team of Nobel Prize winners at Rockefeller University Breaking the mold by launching a clinical trial in just three months versus the 12-month standard in a big pharma firm Why building relationships with big pharma is key as a small biotech company with multiple assets in the pipeline How his lean biotech is running the most rapid proof of concept studies in the market whilst conserving cash and building value Why manufacturing and reliance on CDMOs have been the biggest challenge to his business Dr Ian Walters has over 20 years of leadership and expertise in oncology/immunology drug development and specializes in the evaluation, prioritization and innovation of new therapies for the treatment of severe diseases.  Prior to Portage, Ian spent seven years at Bristol Myers Squibb, where he managed physicians overseeing the international development of more than eight oncology compounds and biomarker and companion diagnostic work. He was a core member of Bristol Myers Squibb’s Strategic Transactions Group evaluating and executing licensing agreements, mergers and acquisitions, clinical collaborations and the company’s immuno-oncology strategy. Prior to BMS, he held positions at PDL BioPharma, Inc., Millennium Pharmaceuticals, Inc. and Sorrento Therapeutics, Inc., leading corporate development, translational medicine, clinical development and medical affairs. Before entering the private sector, Ian was a lead investigator at the Rockefeller University and initiated advanced immunology research to understand the mechanism of action of several compounds. Ian received his M.D. from the Albert Einstein College of Medicine and an MBA from the Wharton School of The University of Pennsylvania. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.  

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with  Ian Walters, CEO and Chairman at Portage Biotech. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Ian, covering: What Ian learned from his time working with a team of Nobel Prize winners at Rockefeller University Breaking the mold by launching a clinical trial in just three months versus the 12-month standard in a big pharma firm Why building relationships with big pharma is key as a small biotech company with multiple assets in the pipeline How his lean biotech is running the most rapid proof of concept studies in the market whilst conserving cash and building value Why manufacturing and reliance on CDMOs have been the biggest challenge to his business Dr Ian Walters has over 20 years of leadership and expertise in oncology/immunology drug development and specializes in the evaluation, prioritization and innovation of new therapies for the treatment of severe diseases.  Prior to Portage, Ian spent seven years at Bristol Myers Squibb, where he managed physicians overseeing the international development of more than eight oncology compounds and biomarker and companion diagnostic work. He was a core member of Bristol Myers Squibb’s Strategic Transactions Group evaluating and executing licensing agreements, mergers and acquisitions, clinical collaborations and the company’s immuno-oncology strategy. Prior to BMS, he held positions at PDL BioPharma, Inc., Millennium Pharmaceuticals, Inc. and Sorrento Therapeutics, Inc., leading corporate development, translational medicine, clinical development and medical affairs. Before entering the private sector, Ian was a lead investigator at the Rockefeller University and initiated advanced immunology research to understand the mechanism of action of several compounds. Ian received his M.D. from the Albert Einstein College of Medicine and an MBA from the Wharton School of The University of Pennsylvania. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

NOW PLAYING

Meet the lean, keen biotech

0:00 59:08

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of Molecule to Market: Inside the outsourcing space?

This episode is 59 minutes long.

When was this Molecule to Market: Inside the outsourcing space episode published?

This episode was published on April 28, 2023.

What is this episode about?

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with  Ian Walters, CEO and Chairman at Portage Biotech. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology...

Can I download this Molecule to Market: Inside the outsourcing space episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!